Information for Investors

NeuralDx represents an opportunity to participate in an historic change to the global mental healthcare market through the development and commercialisation of a technology that aims to provide faster, more accurate objective diagnostic decision support service to GPs specialist psychiatrists and neurologists. The patented technology EVestG™ is addressing this global unmet need for an objective diagnostic service. The A$10 million invested to date has been applied to de-risk the technology and build sound scientific evidence toward EVestG™’s commercialisation and entry into a large global market.